Sanofi
Company & revenue
About Sanofi
Who they are
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders.
Detailed revenue, brand and relationship research has not yet been completed for SNY.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
38
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
63
Fair
Financial Strength
61
Business Quality / Moat
61
Management
77
Growth Quality
31
Risk / Durability
95
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
24
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
33/100
Building Historical Record
Model Score 33/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently sees meaningful weaknesses in the company-strength profile.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
Company-specific research
Questions worth answering for SNY
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can SNY maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is SNY's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is SNY's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify SNY's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of SNY's score?
Essential Investment Snapshot
Wall Street Score
38
Opportunity Score
24
Market Cap
$95.86B
P/E Ratio
75.1
EPS
$0.54
52-Week High
$52.68
52-Week Low
$40.40
Beta
0.28
Intrinsic Value
$9.88
Analyst Target
$49.50
Shares Outstanding
2.44B
Total Revenue
$55.48B
Total Debt
$26.74B
Dividend Yield
6.06%
Liquidation Value / Share
$32.32
Annual Dividend
$2.42
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for SNY
Detected from reported data — verify before acting.Dividend history reported
Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on SNY.
What the Bulls Say
- +Product opportunity: Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, add.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
No strong bearish data point is currently available.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
56
Jul 24, 2026
Change
-18.6
points
Current Score
38
Oct 1, 2026
Category Changes
SNY decreased 18.6 points because Revenue declined by 2.9 points, Capital declined by 28 points, Management declined by 21.1 points.
Negative Contributors
- − Revenue declined by 2.9 points
- − Capital declined by 28 points
- − Management declined by 21.1 points
- − Valuation declined by 74.1 points
- − Buffett declined by 11 points
Projected Score
Projected Score
31
Projected Change
-6.8%
Preliminary comparable-period financial changes suggest decline of approximately 6.8 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$39.92
Intrinsic Value
$9.88
Difference
+$30.04
+304.2% vs IV
Margin of Safety
-304.2%
Related Companies
Drug Manufacturers - GeneralNews
Sanofi, Regeneron Expand Immunology Alliance With New Antibodies
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion
Sanofi, Regeneron Expand DUPIXENT Alliance in Deal Worth Up to €8 Billion
Sanofi, Regeneron to Expand Alliance in Deal Valued at Up to $8 Billion
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial